细胞治疗

Search documents
低空经济缺人?广东这场会上,人大代表建议开设“微专业”
Nan Fang Du Shi Bao· 2025-09-15 12:05
Group 1 - Guangdong has prioritized the cultivation of high-quality talent to support the construction of a modern industrial system, with over 1 million college graduates attracted to work and start businesses in the region by July 2025 [1] - A special meeting was held on September 15 to discuss the acceleration of modern industrial system construction, focusing on high-quality talent cultivation [1] - National representatives provided suggestions on talent cultivation, innovation, and mobility to enhance the talent support for Guangdong's modern industrial system [1] Group 2 - The establishment of "micro-specialties" is recommended to empower emerging industries, particularly in the low-altitude economy, with a focus on interdisciplinary talent [2] - Suggestions include creating a "Low Altitude Regulations and Ethics" interdisciplinary course and a provincial low-altitude economic talent development fund [2] - Emphasis on deepening industry-education integration and practical training to enhance the capabilities of graduates in relevant fields [2] Group 3 - Recommendations for a "Biomedicine Future Industry Talent Training Program" to encourage multi-position training and establish a cross-school "Biomedicine + X" micro-specialty [3] - The proposal to create a talent "reverse flying ground" to separate innovation and application, facilitating targeted talent development [3] - Suggestions to enhance talent retention through regional honor systems and professional communities to reduce talent loss [3] Group 4 - The importance of breaking down barriers to talent mobility between institutions, enterprises, and research platforms is emphasized [4] - Encouragement for innovative enterprises to engage research personnel in applied research to promote two-way talent flow [5] - Recommendations for reforming talent evaluation mechanisms to grant enterprises greater autonomy in talent assessment [5]
生物医学新技术迎新规:法治化护航产业高质量发展
2 1 Shi Ji Jing Ji Bao Dao· 2025-09-15 08:28
生物医学技术作为生物科学领域中发展最快、最具挑战力的技术,既为人类疾病诊疗突破、健康水平提 升提供了新手段,也因技术特性在临床研究与应用过程中,面临着隐私泄露、生物安全风险、公共安全 隐患及社会伦理争议等多重挑战。规范引导生物医学新技术临床研究与转化应用的有序推进,是推动医 学科技进步的关键,更关系到患者的生命安全。 日前,国务院常务会议审议通过《生物医学新技术临床研究和临床转化应用管理条例(草案)》(以下 简称《条例草案》),并明确提出要推动我国生物医学技术创新发展,着力塑造发展新优势,同时坚持 发展和安全并重,依法规范临床研究,保障临床应用质量安全,有效防范各类风险,确保创新成果更好 增进人民健康福祉。 对于《条例草案》的出台意义,上海市卫生和健康发展研究中心主任金春林向21世纪经济报道指 出,"国务院审议通过《条例草案》,标志着我国生物医药产业步入法治化监管的新时代,为产业高质 量发展提供了系统性制度保障。" "其一,这有利于将生物医药产业纳入国家战略性新兴产业范畴,明确其作为新质生产力在高质量发展 中的核心地位,产业将获得更多政策与资源倾斜。其二,《条例草案》推动了全链条创新生态环境的构 建。通过分级 ...
乐城与13家头部生物医药企业签约合作
Hai Nan Ri Bao· 2025-08-31 00:42
会议还进行《乐城先行区生物医学新技术的实践探索与发展机遇》主题推介、《海南省关于进一步 支持生物医药产业高质量发展的若干政策措施》解读、海南自由贸易港封关政策宣介等。 据了解,作为全国唯一的"医疗特区"和海南自贸港建设的重要功能平台,乐城先行区近年来充分运 用国家赋予的"国九条"等特殊政策,逐步构建起覆盖国际创新药械快速引进、临床应用、注册审批及生 产制造的全链条服务体系。同时,积极把握医疗科技革命和产业变革新机遇,在全国率先开展细胞治 疗、基因编辑等生物医学新技术临床转化应用。目前已审批11个前沿医疗技术项目,并在制度创新、风 险防控、数字化管理等关键领域取得系列突破。 海南日报博鳌8月30日电(海南日报全媒体记者 李豌 通讯员 林春茹)8月30日,乐城先行区生物医 学新技术政策推介会暨第一批企业集中签约大会在博鳌乐城国际医疗旅游先行区举行。大会上,乐城先 行区管理局与13家国内头部生物医药企业达成签约合作,预计总投资不少于30亿元。 签约后,各方将结合企业技术优势与海南自贸港及乐城先行区的政策红利,共同推动更多新技术、 新产品、新方案在乐城先行区率先应用,更好满足人民群众健康需求。同时,促进研发中心、生产 ...
第33届广州博览会:服务全国统一大市场建设 书写高质量发展新篇章
Ren Min Ri Bao· 2025-08-21 22:03
Core Viewpoint - The 33rd Guangzhou Expo, scheduled from August 22 to 24, aims to empower high-quality economic and social development in Guangzhou with the theme "Dual Empowerment Promotes Circulation, New Quality Innovations Create the Future" [1] Group 1: Historical Development - The Guangzhou Expo has evolved over 30 years, transitioning through three stages: - Stage 1 (1993-2002): Established a foundation for comprehensive exhibitions focusing on Guangzhou's urban development and trade relations [2] - Stage 2 (2003-2013): Innovated the "comprehensive exhibition + professional exhibition" model, leading to the incubation of specialized exhibitions [2] - Stage 3 (2014-2023): Achieved significant success with specialized exhibitions, including the Guangzhou International Health Industry Expo, certified by the International Exhibition Alliance [2] - From 2024, the Expo will enter a market-oriented reform phase, focusing on strategic emerging industries and aiming for zero financial input from the municipal budget by 2025 [2] Group 2: Highlights of the Current Expo - The current Expo features five major highlights, including: - Expansion and enhancement of exhibition areas, covering diverse fields with a total area of approximately 180,000 square meters, a year-on-year increase of over 50% [3] - The introduction of international collaboration, with over 300 guests from more than 30 countries and organizations participating, showcasing over 2,000 inventions [3] - A focus on domestic demand and regional collaboration, promoting local specialties and tourism resources through dedicated exhibition areas [4] - Presentation of cutting-edge technologies and innovative products, including a special area for robotics and advanced biopharmaceutical technologies [4] Group 3: Economic Collaboration and Development - The Expo aims to build a "dual empowerment" platform to enhance cooperation and economic collaboration among various regions [5] - A strategic framework agreement was signed to strengthen domestic circulation and promote new quality productivity through technology sharing and market connectivity [5] - The Expo serves as a vital platform for activating innovation and supporting the construction of a modern industrial system in Guangzhou, contributing to the coordinated development of the Guangdong-Hong Kong-Macao Greater Bay Area [6]
上海临床转化种子投资基金发布
Sou Hu Cai Jing· 2025-08-04 09:32
Core Insights - The forum "Clinical Transformation and Financial Empowerment" was held in Shanghai, focusing on the bottlenecks in the transformation of medical technology achievements [1] - The forum introduced a pioneering trust company model for intellectual property services and launched the Shanghai Clinical Transformation Seed Investment Fund with an initial scale of 180 million RMB [1][2] - These initiatives signify significant progress in building a systematic and mechanized ecosystem for clinical achievement transformation in Shanghai, aiming to enhance medical innovation [1] Investment Fund Details - The Shanghai Clinical Transformation Seed Investment Fund was established to address the funding gap faced by early clinical innovation projects, often referred to as the "valley of death" [2] - The fund, with an initial scale of 180 million RMB, focuses on early and small investments, collaborating with clinical medical staff to navigate the transformation challenges [2] - The fund will prioritize high-growth potential areas such as innovative medical devices, innovative drugs, cell therapy, and nuclear medicine, aiming to discover and cultivate significant IP in the medical clinical field [2]
两部门:开展重大防控、化学创新药、类器官产品、医疗机器人等计量检测和质量评价关键技术研究
news flash· 2025-07-09 06:54
Core Viewpoint - The State Administration for Market Regulation and the Ministry of Industry and Information Technology have issued the "Measurement Support Action Plan for the Development of New Quality Productive Forces (2025-2030)" focusing on key areas related to public health and biotechnology [1] Group 1: Key Areas of Focus - The plan emphasizes the importance of biotechnology, diagnostic equipment, and drug development in enhancing public health [1] - Specific directions include research on critical technologies for measurement and quality evaluation in pharmaceuticals, vaccines, advanced diagnostic technologies, wearable devices, precision medicine, and testing [1] Group 2: Research and Development Initiatives - Major initiatives will involve significant prevention and control measures, chemical innovative drugs, biopharmaceuticals, high-throughput gene sequencing, cell therapy, biological testing, in vitro diagnostic products, synthetic biology products, organoid products, and medical robots [1] - The plan aims to promote interdisciplinary integration in pharmacology, physiology, and synthetic biology to accelerate the application of related technologies in new drug development, disease treatment, and specialized medical food formulations [1]
国产创新药迎来价值重估
Zheng Quan Ri Bao· 2025-06-13 16:14
Core Viewpoint - The innovative pharmaceutical sector in China is experiencing a significant upward trend, driven by policy support, industry advancements, and capital empowerment, leading to a revaluation of domestic innovative drugs [1][2][4] Policy Support - The Chinese government has been increasing its support for domestic innovative drugs since 2015, establishing a comprehensive policy framework that covers drug research, approval, payment, market access, and internationalization [1] - In January 2023, the State Council issued an opinion to enhance support for drug and medical device innovation, aiming to transform China from a major pharmaceutical country to a strong one [1] - A June 2023 State Council meeting emphasized the need for better coordination in the "three medical" sectors and improving public hospital compensation mechanisms to support pharmaceutical companies in enhancing innovation capabilities [1] Industry Development - The R&D investment in China's pharmaceutical and biotechnology sector is on the rise, with A-share pharmaceutical companies expected to invest over 120 billion yuan in R&D in 2024 [2] - Domestic innovative pharmaceutical companies are transitioning from low-level repetitive innovation to original innovation, producing globally competitive drugs, particularly in cutting-edge fields like ADCs, cell therapy, and gene therapy [2] - There is a surge in the development of GLP-1 class drugs for metabolic diseases, with domestic companies optimizing molecular structures and developing long-acting formulations to catch up with international leaders [2] International Recognition - Chinese innovative drugs and companies are gaining trust in international markets, with significant participation in top global academic conferences, showcasing research achievements [3] - In 2025, over 70 research outcomes led by Chinese scholars are expected to be presented at the ASCO conference, a significant increase from just one ten years ago [3] - In May 2023, a record-breaking overseas licensing deal worth $1.25 billion was made by a Chinese company, indicating strong international confidence in Chinese R&D capabilities and product quality [3] Capital Empowerment - Various local governments have established special funds to subsidize R&D expenses for innovative pharmaceutical companies, supporting their development and industrialization [4] - As of June 13, 2023, the number of pharmaceutical and biotechnology companies listed on the A-share STAR Market reached 109, raising over 170 billion yuan, providing ongoing momentum for innovative drug development [4] - A number of innovative pharmaceutical companies have made significant progress in transitioning from technological breakthroughs to industrial applications, fueled by capital market support [4]
企业家俱乐部成功举办"为品质生活‘胞’驾护航"活动
Sou Hu Cai Jing· 2025-06-10 10:31
Group 1 - The event "Quality Life 'Cell' Escort" was successfully held at the Jitao Medical Activity Center on June 10 [1] - Jitao Medical's General Manager Liu Kainian welcomed guests and introduced the company's development history and advantages in cell technology [3] - The event featured three main modules: exploration of cutting-edge technology, sharing of health knowledge, and personalized consultations, establishing a new paradigm for health management [4] Group 2 - Liu Tianjin, founder of Jitao Health and a PhD from the Shanghai Institute of Biochemistry and Cell Biology, shared insights on "Cell Technology and Life Health Management," highlighting breakthroughs in cell therapy for anti-aging, chronic disease intervention, and cancer prevention [5] - Club Chairman Wang Dawei emphasized the importance of health, happiness, and ambition as core elements of quality life, and expressed the club's commitment to providing customized health solutions in collaboration with Jitao Medical [7] - The event injected new momentum into the club's quality life sector, with plans to continuously integrate quality resources and innovate service models to enhance health and competitiveness in Weifang [9] Group 3 - Jitao Medical Technology Co., Ltd. is a technology-based enterprise founded by a postdoctoral researcher from the Chinese Academy of Sciences and the government-owned Hengjian Group, focusing on the development of immune cell and stem cell therapies, as well as early cancer diagnosis and intervention technologies [13] - The company has developed a tumor early diagnosis platform based on ctDNA methylation detection and has established a cell storage and preparation platform for precision treatment, recognized as one of the first provincial-level new research and development institutions in Shandong [13] - The regional cell tissue bank and preparation center in Weifang has a total investment of over 20 million yuan, featuring a public life science popularization museum and a 1,200 square meter cell storage and preparation center, adhering to international standards for clinical-grade and pharmaceutical-grade cell banks [14]
520临床试验日:“从纸到云”时代,如何破解临床成果转化堵点
2 1 Shi Ji Jing Ji Bao Dao· 2025-05-20 10:39
Group 1: Industry Overview - The biopharmaceutical industry is a strategic emerging industry crucial to national security and public health, currently facing challenges in translating basic research into clinical applications [1] - Clinical trials are identified as a core driver for upgrading the biopharmaceutical industry, with significant room for improvement in resource integration and efficiency [1][2] - The number of IND applications for new drugs has been increasing, reaching 1,241 in 2023, a 31.7% year-on-year growth, marking a five-year high [3] Group 2: Clinical Trial Development - Clinical trials are essential for validating and commercializing research outcomes, serving as a key step for companies and hospitals to enhance their clinical research capabilities [2] - The number of new drug clinical trials in China has nearly doubled from 2018-2020 (2,758 trials) to 2021-2023 (5,216 trials), with antibody-drug conjugates and bispecific antibodies showing significant growth in trial numbers [3][4] - In 2023, China registered 270 clinical trials, surpassing the United States' 222 trials during the same period, indicating a recovery in clinical trial activity [4] Group 3: Quality Control and Regulatory Framework - The quality of clinical trials is emphasized as a critical factor, with ongoing improvements in quality management systems and regulatory standards being necessary for high-quality development [5][6] - The implementation of ICH E6 (R3) from January 2025 is expected to reshape clinical trial design and execution processes, significantly impacting industry quality systems [10] - A comprehensive quality control system is recommended to ensure data integrity and participant safety throughout the clinical trial lifecycle [6][11] Group 4: Digital Transformation in Clinical Trials - The clinical trial industry is entering a digital era, with the integration of new technologies such as artificial intelligence and digital solutions to enhance efficiency and quality [7][8] - Nearly 80% of recent studies have utilized electronic clinical outcome assessments (eCOA), indicating a shift towards more digitalized and automated clinical trials [7] - The use of electronic data capture (EDC) systems is highlighted as a core entry point for data management, improving accuracy and processing efficiency [13]
江苏省人民医院:以健康为中心 多措并举助力肿瘤防治
Ren Min Wang· 2025-04-28 02:37
Group 1: Cancer Prevention and Health Education - The 31st National Cancer Prevention and Control Publicity Week emphasizes the theme "Scientific Cancer Prevention, Healthy Living" [1] - Jiangsu Provincial People's Hospital advocates for a health-centered approach to cancer prevention, focusing on health education and improving public health literacy [1] - The hospital suggests integrating health education into its development plan, establishing dedicated health education departments, and enhancing the scientific literacy of medical staff through training [1] Group 2: Comprehensive Cancer Care - Jiangsu Provincial People's Hospital adopts a multidisciplinary treatment model, establishing specialized centers for lymphoma, gastric tumors, and thyroid cancer to manage patient care throughout the entire process [2] - The hospital has upgraded traditional treatment processes to full-cycle rehabilitation management, incorporating resources from traditional Chinese medicine, nutrition, and rehabilitation [2] - The complexity of lymphoma, with over 100 pathological subtypes, necessitates precise diagnosis and individualized treatment plans, focusing on pre-hospital assessments and post-discharge home management [2] Group 3: Research and Innovation in Cancer Treatment - There is a call for increased research into the mechanisms of lymphoma and drug resistance, as well as the exploration of clinical translation pathways [2] - Advances in basic research have led to the development of innovative therapies such as monoclonal antibodies, bispecific antibodies, and cell therapies, significantly improving clinical outcomes for lymphoma patients [2] - The goal is to translate research and clinical experiences into innovative drugs that effectively serve patients with hematological diseases and lymphomas [2]